Nervoid provides an AI‑powered SaaS platform that automatically analyzes cell microscopy images to detect signaling pathway alterations and rank drug candidates in real time. Integrated directly with screening microscopes, the cloud service delivers instant morphological reports and exportable data for pharmaceutical R&D and biotech labs, speeding hit identification and mechanism‑of‑action insights.
Funding
Funding not disclosed
Founders
Product
Problem
Drug discovery programs often rely on labor-intensive microscopy analysis to infer cellular signaling changes, leading to slow hit identification and delayed mechanism-of-action insights. Manual image interpretation can miss subtle morphological cues, reducing the efficiency of candidate prioritization.
Solution
Nervoid offers an AI-powered computer vision SaaS platform that processes cell microscopy images to automatically detect altered signaling pathways. By integrating directly with existing screening hardware, the system delivers real-time morphological analysis and ranks hit candidates based on inferred pathway activity. Researchers receive instant reports that highlight translatable drug targets, accelerating mechanism discovery and downstream development decisions. The platform’s cloud-based architecture enables scalable deployment across laboratories without the need for specialized AI expertise.
Target Audience
Primary users are pharmaceutical R&D teams and biotech laboratories conducting high-throughput cell-based screening for target validation and lead optimization.
Features
- Direct integration with screening microscopes for seamless image ingestion
- Advanced deep-learning models that extract morphological features and map them to specific signaling pathway alterations
- Automated prioritization of hit candidates with real-time scoring dashboards
- Cloud-hosted SaaS interface for uploading images and receiving instant analysis results
- Exportable data formats compatible with common drug discovery workflow tools